NCT05208060View on ClinicalTrials.gov

Study to Evaluate the Ability of Sublingual MV130 to Induce the Expression of Trained Immunity in Peripheral Blood Cells

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

January 30, 2025

Study Completion Date

December 31, 2025

Conditions
Immune Response
Interventions
BIOLOGICAL

MV130

Treatment administered sublingually

OTHER

Placebo

Treatment administered sublingually

Trial Locations (1)

28040

RECRUITING

Hospital Clínico San Carlos, Madrid

Sponsors

Lead Sponsor

Inmunotek S.L.
All Listed Sponsors
lead

Inmunotek S.L.

INDUSTRY

NCT05208060 - Study to Evaluate the Ability of Sublingual MV130 to Induce the Expression of Trained Immunity in Peripheral Blood Cells | Biotech Hunter | Biotech Hunter